TY - JOUR
T1 - Prognostic impact of CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma
T2 - A multiinstitutional retrospective study
AU - Okumura, Yoshihide
AU - Nakano, Satsuki
AU - Murase, Takayuki
AU - Ueda, Kaori
AU - Kawakita, Daisuke
AU - Nagao, Toshitaka
AU - Kusafuka, Kimihide
AU - Urano, Makoto
AU - Yamamoto, Hidetaka
AU - Kano, Satoshi
AU - Tsukahara, Kiyoaki
AU - Okami, Kenji
AU - Nagao, Toru
AU - Hanai, Nobuhiro
AU - Iwai, Hiroshi
AU - Kawata, Ryo
AU - Tada, Yuichiro
AU - Nibu, Ken Ichi
AU - Inagaki, Hiroshi
N1 - Funding Information:
Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan, Grant/Award Numbers 15K08351 and 17K08746. This study was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan (15K08351 to H. Inagaki and 17K08746 to T. Murase). The authors thank the following collaborators: Masato Nakaguro (Nagoya University Hospital, Nagoya, Japan), Kenichi Taguchi (National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan), Tetsuro Onitsuka (Shizuoka Cancer Center, Mishima, Japan), Yasushi Fujimoto (Nagoya University Graduate School of Medicine, Nagoya, Japan), Kazuo Sakurai (Fujita Health University, Toyoake, Japan), and Naohito Hato (Ehime University School of Medicine, Matsuyama, Japan).
Funding Information:
This study was supported in part by a Grant‐in‐Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan (15K08351 to H. Inagaki and 17K08746 to T. Murase). The authors thank the following collaborators: Masato Nakaguro (Nagoya University Hospital, Nagoya, Japan), Kenichi Taguchi (National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan), Tetsuro Onitsuka (Shizuoka Cancer Center, Mishima, Japan), Yasushi Fujimoto (Nagoya University Graduate School of Medicine, Nagoya, Japan), Kazuo Sakurai (Fujita Health University, Toyoake, Japan), and Naohito Hato (Ehime University School of Medicine, Matsuyama, Japan).
Publisher Copyright:
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Mucoepidermoid carcinoma (MEC) is rare, but the most common primary malignancy of the salivary gland and not infrequent in young individuals. CRTC1/3-MAML2 fusions are frequently detected in MEC and are useful as a diagnostic biomarker. However, there has been debate as to whether the fusions have prognostic significance. In this study, we retrospectively collected 153 salivary gland MEC cases from 11 tertiary hospitals in Japan. As inclusion criteria, the MEC patients in this study had curative surgery as the initial treatment, received no preoperative treatment, and had no distant metastasis at the time of the initial surgery. The MEC diagnosis was validated by a central pathology review by five expert salivary gland pathologists. The CRTC1/3-MAML2 fusions were detected using FISH and RT-PCR. In 153 MEC cases, 90 (58.8%) were positive for CRTC1/3-MAML2 fusions. During the follow-up period, 28 (18.3%) patients showed tumor recurrence and 12 (7.8%) patients died. The presence of the fusions was associated with favorable tumor features. Of note, none of the fusion-positive patients died during the follow-up period. Statistical analysis showed that the presence of the fusions was a prognostic indicator of a better overall survival in the total and advanced-stage MEC cohorts, but not in the early-stage MEC cohort. In conclusion, CRTC1/3-MAML2 fusions are an excellent biomarker for favorable overall survival of patients with salivary gland MEC.
AB - Mucoepidermoid carcinoma (MEC) is rare, but the most common primary malignancy of the salivary gland and not infrequent in young individuals. CRTC1/3-MAML2 fusions are frequently detected in MEC and are useful as a diagnostic biomarker. However, there has been debate as to whether the fusions have prognostic significance. In this study, we retrospectively collected 153 salivary gland MEC cases from 11 tertiary hospitals in Japan. As inclusion criteria, the MEC patients in this study had curative surgery as the initial treatment, received no preoperative treatment, and had no distant metastasis at the time of the initial surgery. The MEC diagnosis was validated by a central pathology review by five expert salivary gland pathologists. The CRTC1/3-MAML2 fusions were detected using FISH and RT-PCR. In 153 MEC cases, 90 (58.8%) were positive for CRTC1/3-MAML2 fusions. During the follow-up period, 28 (18.3%) patients showed tumor recurrence and 12 (7.8%) patients died. The presence of the fusions was associated with favorable tumor features. Of note, none of the fusion-positive patients died during the follow-up period. Statistical analysis showed that the presence of the fusions was a prognostic indicator of a better overall survival in the total and advanced-stage MEC cohorts, but not in the early-stage MEC cohort. In conclusion, CRTC1/3-MAML2 fusions are an excellent biomarker for favorable overall survival of patients with salivary gland MEC.
UR - http://www.scopus.com/inward/record.url?scp=85090998462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090998462&partnerID=8YFLogxK
U2 - 10.1111/cas.14632
DO - 10.1111/cas.14632
M3 - Article
C2 - 32860299
AN - SCOPUS:85090998462
SN - 1347-9032
VL - 111
SP - 4195
EP - 4204
JO - Cancer Science
JF - Cancer Science
IS - 11
ER -
